BioLineRx Ltd. - ADR

Name: BioLineRx Ltd. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: BioLineRx Ltd. - ADR

Stock Card

$2.69

$-0.08 (-2.72%)

As on 28-Aug-2026 13:33EDT

Market cap

$12 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

BioLineRx - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.56 High: 2.72

52 Week Range

Low: 2.16 High: 4.56

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.1
Debt to Equity

0.2
Book Value

$--
EPS

$-2.1
Face value

--
Shares outstanding

4,368,295

10 Years Aggregate

CFO

$-206.19 Mln

EBITDA

$-229.81 Mln

Net Profit

$-248.64 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
BioLineRx - ADR	-3.1	-4.7	-20.3	-27.0	-62.2	-52.8	-41.3
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
BioLineRx - ADR	-67.6	-86.1	166.1	-71.1	-19.0	12.0	-65.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
BioLineRx - ADR	2.7	12.3	1.4	-8.9	-616.0	-43.7	--	0.8
Cellectis S.A. - ADR	3.4	342.9	56.6	-65.4	-121.7	-111.8	--	8.4
DBV Technologies S.A. - ADR	13.7	914.4	0.0	-175.9	--	-106.8	--	5.6
Galapagos NV - ADR	28.0	1,862.3	1,043.8	488.8	-19.0	16	3.2	0.5
Molecular Partners AG (MOLN)	4.5	165.1	0.0	-64.2	--	-78.4	--	1.9
Pharming Group N.V. ADS each representing 10 (PHAR)	11.7	838.7	366.5	9.3	8.3	3.4	84.6	3.1
Prime Medicine	3.6	614.9	4.1	-187.9	-4,613.1	-233.9	--	0.3
Silence Therapeutics PLC (SLN)	13.4	824.8	0.6	-59.9	-9,892.6	-118.9	--	21.3
Valneva SE - ADR	6.4	660.0	143.5	-158.2	-80.2	-168.9	--	6.9
Zai Lab - ADR	26.1	2,920.0	449.6	-188.2	-41.1	-28.5	--	4.8

Shareholding Pattern

View Details

About BioLineRx - ADR

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and... APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Read more

Chief Executive Officer

Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer

Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Headquarters

Hevel Modi'in
Website

https://www.biolinerx.com

FAQs for BioLineRx - ADR

What is the current share price of BioLineRx Ltd - ADR Today?

The share price of BioLineRx Ltd - ADR is $2.69 (NASDAQ) as of 28-Aug-2026 13:33 EDT. BioLineRx Ltd - ADR has given a return of -62.17% in the last 3 years.

What is the current PB & PE ratio of BioLineRx Ltd - ADR?

Since, TTM earnings of BioLineRx Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of BioLineRx Ltd - ADR is 0.76 times as on 21-Aug-2026, a 84 discount to its peers’ median range of 4.82 times.

PE & PB ratio at the end of financial year.